Published on October 8, 2015
During the last couple of years, we’ve focused our efforts on developing our cardiovascular diagnostics. This emphasis has helped establish our place as one of the leading global providers of cardiovascular genetic diagnostics. As of March 2016, we are taking the company to a next level by radically expanding our…
Read morePublished on September 2, 2015
Genetic basis of pulmonary arterial hypertension (PAH) is well recognised but still rarely utilized in diagnostics setting. Diagnostic yield of comprehensive multi-gene panels in PAH is relatively unknown as current knowledge is gathered from studies evaluating only one gene at a time in a heterogenous patient populations. Finnish PAH…
Read morePublished on August 27, 2015
To explore the underlying genetic defects of dilated cardiomyopathy (DCM) we applied OS-Seq technology as a novel comprehensive diagnostic tool. Despite our increasing understanding of the genetics of DCM the genetic basis of the disease is still poorly understood. We were able to identify pathogenic variants in 47.6% of the…
Read morePublished on April 13, 2015
We are continuously participating in events around the world. Come meet us at the following conferences during spring and summer 2015. More details about our participation, booth number etc. are also found on our Facebook page. HRS – Heart Rhythm 2015 36th Annual Scientific…
Read morePublished on April 9, 2015
Sequencing of channelopathy genes with the BpG Arrhythmia Panel revealed a de novo mutation in the CACNA1C gene in an adolescent with ventricular fibrillation but normal development, consequently not only expanding the phenotype of Timothy Syndrome Type 2 but also demonstrating the power of large gene panels. The standard has been to select specific gene tests for patients with established…
Read morePublished on March 27, 2015
We have a tradition of naming our sequencing machines after famous robots. Our latest system is called Sampo. In the Finnish national epoch compiled by Elias Lönnrot, Kalevala, Sampo is described as a refiner engine that brought prosperity to its owner. Pretty witty, huh? Currently, we are using Illumina’s MiSeqs…
Read morePublished on March 25, 2015
Read morePublished on March 25, 2015
Finnish business magazine Talouselämä has released its take on the 20 most promising start-ups in Finland. Blueprint Genetics is one of the companies! Read more… (Order Talouselämä or try ’Summa’ one month for free to read the full story.)…
Read morePublished on March 24, 2015
The 2015 Annual Clinical Genetics Meeting (ACMG) marks an important milestone for us at Blueprint Genetics, one of the leading laboratories in cardiovascular genetics. At this meeting we’re excited to announce our new and improved service model, plus our upcoming sales launch in the US. We’re opening new facilities…
Read morePublished on December 18, 2014
Blueprint Genetics thanks all hospitals and clinics, which have collaborated with us and utilized our diagnostic services during year 2014 and wishes all of you a Happy New Year 2015! During 2014 our customer base has exceeded over 90 clinics and hospitals in 31 countries. From these hospitals we have…
Read morePublished on November 3, 2014
Blueprint Genetics launches new genetic diagnostic tests for Becker and Duchenne muscular dystrophies and an updated panel for Emery-Dreifuss muscular dystrophy with the addition of titin (TTN) gene. In line with our other diagnostic panels, we target the sequencing to all protein coding exons, exon-intron boundaries and other regions with…
Read morePublished on August 29, 2014
Helsinki, Finland – August 29, 2014 – Blueprint Genetics is glad to announce that Inventure and Avohoidon Tutkimussäätiö, a Finnish foundation, have joined the existing investors of the company. Previously, the company has been financed by Finnish business angels and Tekes, the Finnish Funding Agency for Innovation. The funding for Blueprint Genetics now totals…
Read morePublished on August 29, 2014
Blueprint Genetics is glad to announce that Inventure and Avohoidon Tutkimussäätiö, a Finnish foundation, have joined the existing investors of the company. Previously, the company has been financed by Finnish business angels and Tekes, the Finnish Funding Agency for Innovation. The funding for Blueprint Genetics now totals $3.9 million, allowing the company to accelerate…
Read morePublished on August 29, 2014
Blueprint Genetics (BpG) is proud to publish extensive validations for NGS panels in detection of single nucleotide polymorphisms (SNPs) and small insertions & deletions (indels). It is widely recognized that sequencing quality has significant impact on diagnostic yield when utilizing NGS technologies. BpG´s mission is to provide the highest possible…
Read morePublished on August 6, 2014
BpG Periodic Fever Syndrome Panel – New Panel Including 9 Genes Blueprint Genetics continues launching comprehensive next-generation sequencing (NGS) tests by releasing a best in class diagnostic panel for periodic fever syndromes (PFS). BpG Periodic Fever Syndrome Panel is the first effective genetic diagnostics tool for familial Mediterranean fever…
Read morePublished on May 6, 2014
Note 06/2018: The content of our cardiology panels has since been updated. To find the latest information what genes we have in our cardiology panels, please see cardiology panels here. If you cannot find the gene you are looking for, please contact our support@blueprintgenetics.com for further information. Blueprint…
Read morePublished on April 24, 2014
Following the successful launch of our index diagnostic panels the number of family members tested at our laboratory has increased significantly during past months. The risk stratification of family members is one of the major reasons for genetic testing and we want to lower the barrier of testing further and…
Read morePublished on March 10, 2014
Blueprint Genetics launches new genetic diagnostic tests for Becker and Duchenne muscular dystrophies and an updated panel for Emery-Dreifuss muscular dystrophy with the addition of titin (TTN) gene. In line with our other diagnostic panels, we target the sequencing to all protein coding exons, exon-intron boundaries and other regions with…
Read morePublished on February 14, 2014
In 2013 Blueprint Genetics launched 14 comprehensive diagnostic NGS panels for hereditary cardiovascular diseases and certain neurological disorders. As previously, our service with inclusive clinical statements and interpretations has been continuing to receive excellent feedback from our customers. The number of ordering hospitals has been increasing and to date physicians…
Read morePublished on January 15, 2014
Blueprint Genetics (BpG) is looking for a highly motivated and exceptional geneticist or clinical geneticist for a full-time position, starting 1st of April 2014 or as negotiated. BpG is a Next Generation Sequencing start-up company based in Helsinki, Finland. We are a team of eleven professionals running a clinical grade…
Read moreCommunication manager